Tepha raises $4.3m for biomaterial development:
This article was originally published in Clinica
Tepha, a private developer of medical devices used in surgical repair and regenerative medicine, has secured $4.3m in financing from The Vertical Group, Integra Ventures and Novartis Venture Fund. The Cambridge, Massachusetts-based company says it will use the proceeds to complete FDA 510(k) filings for its debut range of TephaFLEX products. TephaFLEX, a polyester biomaterial made from a natural metabolite and which degrades "in a cell-friendly manner", is currently being developed by Tepha for several applications including suture, surgical mesh and patch products, tissue repair and tissue engineered cardiovascular devices.
You may also be interested in...
Resolution Medical teamed up with Carbon to introduce more than one million 3D-printed nasal swabs a week to address the shortage for COVID-19 testing.
Early results from the Low-Risk Bicuspid study of the Evolut transcatheter aortic valve replacement system showed low rates of all-cause mortality or stroke.
The reality is that many trials requiring hospital based tests and interventions cannot be replaced, but crisis will spur take up where practical.